Decentralised clinical trials: ethical opportunities and challenges

Area of Science:

• Clinical Research
• Health Policy
• Digital Ethics

Background:

• The COVID-19 pandemic accelerated the adoption of decentralised clinical trials (DCTs), which utilize digital tools to conduct research remotely.
• DCTs offer potential benefits such as reduced participant burden and lower trial costs, alongside ensuring participant safety and research integrity.
• Regulatory bodies like the US Food and Drug Administration have issued guidance for implementing DCTs, reflecting growing interest from sponsors and investigators.

Purpose of the Study:

• To identify and categorize the distinct ethical challenges posed by decentralised clinical trials.
• To propose practical strategies for addressing these ethical issues.
• To advocate for the development of clear ethical standards for DCTs.

Main Methods:

• The study synthesizes insights from traditional research ethics and digital ethics frameworks.
• Ethical issues are systematically grouped into three key areas: participant safety and rights, scientific validity, and ethics oversight.
• The report draws on existing guidance and ethical principles to inform its recommendations.

Main Results:

• Decentralised clinical trials present unique ethical considerations that require heightened vigilance.
• Key ethical challenges span participant safety and rights, ensuring scientific validity, and maintaining robust ethics oversight.
• Existing ethical frameworks need adaptation to adequately address the complexities of digitally-enabled research.

Conclusions:

• Addressing the ethical challenges of DCTs is crucial for their responsible expansion.
• Developing specific ethical standards for decentralised clinical trials is necessary.
• Proactive ethical analysis and management are essential for maintaining public trust and research integrity in the evolving landscape of clinical research.